Formosa Pharmaceuticals (TPE:6838) Piotroski F-Score: 3 (As of Jul. 14, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6838 Formosa Pharmaceuticals Inc TPE:6838
48 GF Score
Price NT$23.60
GF Value NT$14.25
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Formosa Pharmaceuticals Piotroski F-Score?

Formosa Pharmaceuticals TPE:6838 -1.67% 48 Piotroski F-Score is 3 as of Jul. 14, 2026, which is at its 10-year median of 3.00. GuruFocus rates TPE:6838 with a GF Score™ of 48/100 and a GF Value™ of NT$14.25 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,333 Biotechnology companies, Formosa Pharmaceuticals ranks better than 54.69% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Formosa Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Formosa Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

TPE:6838' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 5
Current: 3

During the past 7 years, the highest Piotroski F-Score of Formosa Pharmaceuticals was 5. The lowest was 3. And the median was 3.

Formosa Pharmaceuticals  (TPE:6838) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Formosa Pharmaceuticals Piotroski F-Score Related Terms


Formosa Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Formosa Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formosa Pharmaceuticals Piotroski F-Score Chart

Formosa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 3.00 5.00 3.00

Formosa Pharmaceuticals Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 N/A 4.00 5.00 3.00

TPE:6838 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Formosa Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formosa Pharmaceuticals Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formosa Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Formosa Pharmaceuticals's Piotroski F-Score falls into.


TPE:6838
48GF Score
Formosa Pharmaceuticals Inc TPE:6838
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was -40.745 + 64.337 + -59.192 + -47.965 = NT$-83.57 Mil.
Cash Flow from Operations was -76.913 + 84.22 + -26.993 + -75.957 = NT$-95.64 Mil.
Revenue was 0.594 + 4.764 + 0.911 + 3.226 = NT$9.50 Mil.
Gross Profit was -0.666 + 3.759 + -5.199 + 0.508 = NT$-1.60 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(2112.272 + 2059.702 + 2148.825 + 2106.132 + 2071.234) / 5 = NT$2099.633 Mil.
Total Assets at the begining of this year (Dec24) was NT$2,112.27 Mil.
Long-Term Debt & Capital Lease Obligation was NT$20.41 Mil.
Total Current Assets was NT$1,515.93 Mil.
Total Current Liabilities was NT$166.42 Mil.
Net Income was -19.471 + -96.849 + -46.047 + -38.647 = NT$-201.01 Mil.

Revenue was 127.8 + 5.328 + 4.333 + 5.895 = NT$143.36 Mil.
Gross Profit was 111.825 + 3.871 + 0.638 + 2.656 = NT$118.99 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(1726.781 + 1737.251 + 1524.93 + 2149.839 + 2112.272) / 5 = NT$1850.2146 Mil.
Total Assets at the begining of last year (Dec23) was NT$1,726.78 Mil.
Long-Term Debt & Capital Lease Obligation was NT$20.30 Mil.
Total Current Assets was NT$1,727.79 Mil.
Total Current Liabilities was NT$197.95 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Formosa Pharmaceuticals's current Net Income (TTM) was -83.57. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Formosa Pharmaceuticals's current Cash Flow from Operations (TTM) was -95.64. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-83.565/2112.272
=-0.03956167

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-201.014/1726.781
=-0.11640967

Formosa Pharmaceuticals's return on assets of this year was -0.03956167. Formosa Pharmaceuticals's return on assets of last year was -0.11640967. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Formosa Pharmaceuticals's current Net Income (TTM) was -83.57. Formosa Pharmaceuticals's current Cash Flow from Operations (TTM) was -95.64. ==> -95.64 <= -83.57 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=20.411/2099.633
=0.00972122

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=20.304/1850.2146
=0.01097386

Formosa Pharmaceuticals's gearing of this year was 0.00972122. Formosa Pharmaceuticals's gearing of last year was 0.01097386. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=1515.929/166.417
=9.10921961

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=1727.79/197.951
=8.72837217

Formosa Pharmaceuticals's current ratio of this year was 9.10921961. Formosa Pharmaceuticals's current ratio of last year was 8.72837217. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Formosa Pharmaceuticals's number of shares in issue this year was 150.977. Formosa Pharmaceuticals's number of shares in issue last year was 141.845. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-1.598/9.495
=-0.1682991

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=118.99/143.356
=0.83003153

Formosa Pharmaceuticals's gross margin of this year was -0.1682991. Formosa Pharmaceuticals's gross margin of last year was 0.83003153. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=9.495/2112.272
=0.00449516

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=143.356/1726.781
=0.08301921

Formosa Pharmaceuticals's asset turnover of this year was 0.00449516. Formosa Pharmaceuticals's asset turnover of last year was 0.08301921. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Formosa Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Formosa Pharmaceuticals (TPE:6838) has a Piotroski F-Score of 3 as of Jul. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Formosa Pharmaceuticals and its competitors. This is near median its historical median of 3.00. Over the past decade, Formosa Pharmaceuticals' Piotroski F-Score has ranged from 3.00 to 5.00. According to the industry distribution chart, Formosa Pharmaceuticals ranks #604 out of 1333 companies in the Biotechnology industry, placing it in the top 45.3%.
Is Formosa Pharmaceuticals' Piotroski F-Score too high?
Formosa Pharmaceuticals' current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Formosa Pharmaceuticals' value of 3 is 0% at this industry median. Based on the distribution chart, Formosa Pharmaceuticals ranks #604 out of 1333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Formosa Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Formosa Pharmaceuticals' Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formosa Pharmaceuticals ranks #604 out of 1333 companies for Piotroski F-Score. This puts Formosa Pharmaceuticals in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Formosa Pharmaceuticals' value of 3 is 0% at this benchmark. Historically, Formosa Pharmaceuticals' own Piotroski F-Score has ranged from 3.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Formosa Pharmaceuticals has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formosa Pharmaceuticals's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Formosa Pharmaceuticals and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formosa Pharmaceuticals's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Formosa Pharmaceuticals (TPE:6838) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.25, compared to a current price of NT$23.60 — trading 65.6% above its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 0% at the Biotechnology industry median of 3.00. Formosa Pharmaceuticals' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Formosa Pharmaceuticals (TPE:6838), the current Piotroski F-Score is 3 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formosa Pharmaceuticals (TPE:6838) Overvalued in 2026?

Based on GuruFocus' analysis, Formosa Pharmaceuticals stock appears to be overvalued. The current stock price of NT$23.60 is trading 65.6% above its estimated GF Value™ of NT$14.25. GuruFocus considers Formosa Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TPE:6838:

  • Piotroski F-Score: 3 (near median its 10-year median of 3.00)
  • GF Value™: NT$14.25 vs. price of NT$23.60 (65.6% above fair value)
  • GF Score™: 48/100 with 3 warning signs
  • Industry Position: 0% at the Biotechnology median (#604 of 1333)

No single metric tells the full story. See the TPE:6838 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Formosa Pharmaceuticals Business Description

Address No. 57, Fuxing North Road, 8th Floor-6, Songshan District, Taipei, TWN, 105
Formosa Pharmaceuticals Inc is engaged in new drug development and transfers. Its Product pipeline includes TSY-110, TSY-120, TSY-310, APP13007 and APP13002.
48GF Score

Get the complete analysis for TPE:6838

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.60
Price
NT$14.25
GF Value